Interações de Rifaximina

Rifaximina (Xifaxan), antibiótico, tem 59 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 0; moderadas: 31; leves: 28; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações moderadas (31)

  • Abrocitinibeinibidor da JAKModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • AmiodaronaantiarrítmicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Cetoconazolantifúngico azólicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • CiclosporinaimunossupressorModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Claritromicinaantibiótico macrolídeoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Darunavir + cobicistateantirretroviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Diltiazembloqueador dos canais de cálcioModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • DronedaronaantiarrítmicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • EtravirinaantirretroviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Flibanserinadepressor do SNCModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Itraconazolantifúngico azólicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Ivacaftorinibidor da CYP3A4Moderada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Lapatinibeinibidor da glicoproteína PModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Ledipasvir + sofosbuvirantiviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Lopinavir + ritonavirantirretroviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Mirabegronaagonista beta-adrenérgicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Mitapivateindutor da CYP3A4Moderada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Nilotinibemedicamento que prolonga o intervalo QTModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Nirmatrelvir + ritonavirantiviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Posaconazolantifúngico azólicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • PropafenonaantiarrítmicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • QuinidinaantiarrítmicoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Ranolazinamedicamento que prolonga o intervalo QTModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • RitonavirantirretroviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Sofosbuvir + velpatasvirantiviralModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Suvorexantosedativo-hipnóticoModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • Ticagrelorantiagregante plaquetárioModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • VarfarinaanticoagulanteModerada

    Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. (bula de Rifaximina, Interações medicamentosas)

  • Verapamilbloqueador dos canais de cálcioModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

  • ZonisamidaanticonvulsivanteModerada

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

Menções leves (28)

  • Aprepitantoinibidor da CYP3A4Leve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Armodafinilaestimulante do SNCLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Bosentanaindutor da CYP3A4Leve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • CarbamazepinaanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • CenobamatoanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • ClobazambenzodiazepínicoLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Deferasiroxsuplemento de ferroLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • DexametasonacorticosteroideLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • EfavirenzantirretroviralLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • EslicarbazepinaanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • FenitoínaanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • FenobarbitalbarbitúricoLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Fentermina + topiramatoestimulante do SNCLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • FosfenitoínaanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • GriseofulvinaantifúngicoLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Lorlatinibeindutor da CYP3A4Leve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Mitotanoindutor da CYP3A4Leve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Modafinilaestimulante do SNCLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Nafcilinaantibiótico da classe das penicilinasLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • NevirapinaantirretroviralLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • OxcarbazepinaanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • PrimidonaanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • RifabutinaantibióticoLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • RifampicinaantibióticoLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • RifapentinaantibióticoLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • Suzetriginaindutor da CYP3A4Leve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

  • TopiramatoanticonvulsivanteLeve

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (bula de Rifaximina, Interações medicamentosas)

Verifique Rifaximina com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.